資源描述：
《Optimized Transient MCAO Protocol.》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫。
1、UseofanOptimizedTransientOcclusionoftheMiddleCerebralArteryProtocolfortheMouseStrokeModelZahoorAhmadShah,PhD,*KhodadadNamiranian,MD,*JudyKlaus,RN,*KathyKibler,BS,*andSylvainDoré,PhD*Intraluminalocclusionofthemiddlecerebralarteryinrodentsiswidelyusedforinvestigatingcerebralischemiaandreperfusion
2、injury.Twotypesof?lamentsusedforocclusionweretestedintermsofsurgicalsuccess,incidenceofsubarachnoidhemorrhage,andmortality:astandard6-0mono?lamentcoatedwithmethylmethacrylateglue(rigidprobe)andan8-0mono?lamentcoatedwithsilicone(?exibleprobe).In98wild-type(WT)mice,the?exibleprobeproducedsigni?-c
3、antly(P.05)moresuccessfulstrokes(73.5%)thantherigidprobe(46.6%).Theincidencesofsubarachnoidhemorrhage(3.7%)andmortality(5.6%)withthe?exibleprobeweresigni?cantlylowerthanthosewiththerigidprobe(26.6%and11.1%,respectively).Rigidand?exibleprobeswerealsocomparedinhemeoxygenase1knockout(n17)andWTli
4、ttermates(n17),becauseknockoutmicehavebeensuggestedtohavemorefragilebloodvessels.Allmicereceivingthe?exibleprobehadsuccessfulstrokes,withnocasesofsubarachnoidhemorrhageormortality;however,withtherigidprobe,thesuccessratewasonly80%intheWTmiceand60%intheknockoutmice.Theratesofsubarachnoidhemorrh
5、ageandmortalitywerealsosigni?cantlyhigherwiththerigidprobeinbothgenotypes,buttheinfarctvolumesproducedbyeachtypeofprobedidnotdiffersigni?cantlybetweenthe2groups.Weconcludethatthe?exiblesilicone-coated8-0probeissuperiortothemorerigidglue-coatedprobe,becauseitproducesinfarctvolumesofequalsizewith
6、ahighersuccessrateandlowerriskofsubarachnoidhemorrhageandmortality.KeyWords:Infarctionischemiamiddlecerebralarteryocclu-sionsilicone?lament.?2006byNationalStrokeAssociationThethird-leadingcauseofdeathintheUnitedStates,havefailedinclinicaltrials.Thesefailureshaveledtostrokehasahugeeconomicimpact
7、andproducessignif-concernsregardingthereproducibilityofpreclinical1icantfamilyburdens.Currentstrategiesfortreatingstudiesinvolvingtransientischemicbraininjurymodelsstrokeareverylimited.Mostnewdrugsthathavere-thatuseintraluminal?la
